Fig. 8

a Adhesion assay of MM1.S exo on hTERT-MSCs: pre-treatment of hTERT-MSCs cells with MM1.S exo for 48 h increases MM1.S cell adhesion to mesenchymal cells. Treatment with exosomes pretreated with anti-AREG mAb reduces this effect. Right panel: a representative phase contrast micrograph showing the adhesion of MM1.S cells to exosome-treated hTERT-MSCs monolayer. b Evaluation by quantitative Real Time PCR of mRNA expression of OPG and RANKL in hTERT-MSC treated for 14 days with MM1.S exosomes in osteogenic differentiation medium (diff) (*p ≤ 0.05; **p ≤ 0.01). c IL8 mRNA expression was evaluated by real-time PCR in hTERT-MSCs treated for 24 or 48 h with MM1.S exosomes pretreated or not with anti-AREG mAb for 24 and 48 h. d IL8 protein release was evaluated by ELISA assay in the conditioned medium of hTERT-MSCs monolayer after 48 h treatment with MM1.S exosomes pretreated or not with anti-AREG mAb. *Exo vs untreated (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001); ^#Exo+AREG mAb vs Exo (^#p ≤ 0.05; ^##p ≤ 0.01). e Evaluation by quantitative real-time PCR of mRNA expression of CTSK and MMP9 in CD14⁺ monocytes untreated or treated for 6 days with rIL8, with the conditioned medium of BMMSC cells treated with MM1.S exosomes with or without SB225002 (*p ≤ 0.05; **p ≤ 0.01)